Literature DB >> 21820815

Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers.

Paweł Stawerski1, Małgorzata Wągrowska-Danilewicz, Olga Stasikowska-Kanicka, Marian Danilewicz.   

Abstract

YKL-40 is a glycoprotein secreted by numerous human cells, such as cartilage, synovial, and endothelial cells. The biological role of YKL-40 has not yet been fully unveiled, however, its participation is perceived in angiogenesis, growth, proliferation, differentiation, and remodeling processes. The primary goal of our study was to evaluate possible differences in tissue immunoexpression of YKL-40, assumed between high grade and low-grade ovarian cancers and between the above-mentioned cancer types and benign lesions. Another purpose was to find out whether immunoexpression of the studied protein could correlate with the tumor proliferation process, evaluated by Ki-67 immunoexpression. The analysis comprised 45 women, diagnosed and treated for epithelial ovarian tumors at the Medical University of Lodz between 1997 and 2002. YKL-40 protein immunoexpression was semiquantitatively assessed, whereas immunoexpression of Ki-67 was evaluated using a computer image analysis system. Significantly higher immunoexpression values of both examined proteins were observed in high-grade serous ovarian cancers vs. low-grade and benign tumors. Moreover, a significant positive correlation was identified between the immunoexpressions of YKL-40 and Ki-67 proteins in the studied groups of tumors. In conclusion, the obtained data suggest an overt prominence of TKL-40 tissue immunoexpression of YKL-40 in high-grade serous ovarian tumors, which could then be approached as a helpful, additional marker to identify more aggressive ovarian cancers.
Copyright © 2011. Published by Elsevier GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820815     DOI: 10.1016/j.prp.2011.06.008

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

1.  High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer.

Authors:  Dong Wang; Bo Zhai; Fengli Hu; Chang Liu; Jinpeng Zhao; Jun Xu
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

2.  Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.

Authors:  Anita Monika Chudecka-Głaz; Aneta Alicja Cymbaluk-Płoska; Janusz Leszek Menkiszak; Agnieszka Monika Sompolska-Rzechuła; Aleksandra Izabela Tołoczko-Grabarek; Izabella Anna Rzepka-Górska
Journal:  J Ovarian Res       Date:  2014-06-10       Impact factor: 4.234

3.  Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma.

Authors:  Xin Zheng; Shan Xing; Xiao-Min Liu; Wen Liu; Dan Liu; Pei-Dong Chi; Hao Chen; Shu-Qin Dai; Qian Zhong; Mu-Sheng Zeng; Wan-Li Liu
Journal:  BMC Cancer       Date:  2014-07-07       Impact factor: 4.430

4.  Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.

Authors:  Ying-Cheng Chiang; Han-Wei Lin; Chi-Fang Chang; Ming-Cheng Chang; Chi-Feng Fu; Tsung-Ching Chen; Shu-Feng Hsieh; Chi-An Chen; Wen-Fang Cheng
Journal:  Oncotarget       Date:  2015-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.